Form 4: Aerovate Therapeutics Officer Benjamin T. Dake Executes Stock Option and Sells Shares Under 10b5-1 Plan

Benjamin T. Dake, an officer at Aerovate Therapeutics, exercised stock options and sold shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Summary

• On April 17, 2024, Benjamin T. Dake, President, Chief Operating Officer, and Secretary of Aerovate Therapeutics, Inc. executed a transaction involving the company's common stock.
• Dake exercised stock options to acquire 6,853 shares at a price of $2.14 per share.
• Simultaneously, Dake sold 6,447 shares at a weighted average price of $22.3151, 338 shares at a weighted average price of $23.1699, and 68 shares at a weighted average price of $23.97.
• These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on November 16, 2023.
• Following these transactions, Dake directly owns 1,291 shares of common stock and 95,936 derivative securities (stock options).

Sentiment

Score: 6

Explanation: Neutral sentiment. The filing reflects routine transactions under a pre-existing trading plan. There's no indication of unusual activity or cause for alarm, but also no specific positive catalyst.

Positives

• The transactions were executed under a pre-arranged Rule 10b5-1 trading plan, which can mitigate concerns about insider trading.

Risks

• Executive stock sales can sometimes be perceived negatively by investors, although the pre-planned nature of the sales mitigates this risk.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders. The use of a 10b5-1 plan is a common practice to allow insiders to sell shares without raising concerns about trading on non-public information.

Comparison to Industry Standards

• The use of Rule 10b5-1 trading plans is a common practice among executives at publicly traded companies, including those in the biotechnology sector like Aerovate Therapeutics.
• Similar transactions are regularly reported by officers and directors of companies like United Therapeutics, Vertex Pharmaceuticals, and Gilead Sciences.
• The vesting schedule of the employee stock options, with monthly installments over 48 months, is a standard practice in employee compensation packages.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the sale of shares by an officer, but the pre-planned nature of the sales mitigates potential concerns.

Key Dates